Degos disease

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Degos disease | |
|---|---|
| Synonyms | Malignant atrophic papulosis |
| Pronounce | N/A |
| Specialty | Dermatology, Rheumatology |
| Symptoms | Skin lesions, abdominal pain, neurological symptoms |
| Complications | Bowel perforation, stroke, myocardial infarction |
| Onset | Typically in adulthood |
| Duration | Chronic |
| Types | N/A |
| Causes | Unknown |
| Risks | Possible genetic predisposition |
| Diagnosis | Clinical diagnosis, skin biopsy |
| Differential diagnosis | Lupus erythematosus, scleroderma, vasculitis |
| Prevention | N/A |
| Treatment | Anticoagulants, immunosuppressants, plasmapheresis |
| Medication | N/A |
| Prognosis | Variable; can be fatal if systemic |
| Frequency | Rare |
| Deaths | N/A |
A rare vasculopathy affecting the skin and internal organs
Degos disease, also known as malignant atrophic papulosis, is a rare vasculopathy characterized by distinctive skin lesions and potential involvement of internal organs. The disease is named after the French dermatologist Robert Degos, who first described it in 1941.
Clinical presentation[edit]
Degos disease typically presents with small, erythematous papules that evolve into porcelain-white atrophic scars with a surrounding telangiectatic rim. These lesions are most commonly found on the trunk and extremities. The disease can be divided into two forms: a benign cutaneous form and a systemic form that involves internal organs.
Cutaneous manifestations[edit]
The cutaneous form of Degos disease is characterized by the presence of multiple papules that develop into atrophic scars. These lesions are pathognomonic and are often the first sign of the disease. The skin lesions are usually asymptomatic but can be cosmetically concerning for patients.
Systemic involvement[edit]
In the systemic form of Degos disease, internal organs such as the gastrointestinal tract, central nervous system, and cardiovascular system may be affected. This can lead to serious complications, including bowel perforation, stroke, and myocardial infarction. The systemic form is associated with a poorer prognosis compared to the cutaneous form.
Pathophysiology[edit]
The exact cause of Degos disease is unknown, but it is believed to be an autoimmune process that leads to occlusion of small and medium-sized blood vessels. This results in tissue ischemia and the characteristic skin and organ lesions. Histopathological examination of skin lesions reveals wedge-shaped dermal necrosis and a lymphocytic infiltrate.
Diagnosis[edit]
Diagnosis of Degos disease is primarily clinical, based on the characteristic skin lesions. A skin biopsy can confirm the diagnosis by demonstrating the typical histopathological features. Additional investigations may be required to assess for systemic involvement, including imaging studies and endoscopy.
Management[edit]
There is no cure for Degos disease, and treatment is primarily supportive. Management focuses on alleviating symptoms and preventing complications. Antiplatelet agents, anticoagulants, and immunosuppressive therapies have been used with varying success. Regular monitoring for systemic involvement is crucial.
Prognosis[edit]
The prognosis of Degos disease varies depending on the extent of systemic involvement. The cutaneous form generally has a benign course, while the systemic form can be life-threatening due to complications such as bowel perforation and stroke.
See also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
